Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:346237.
doi: 10.4061/2010/346237. Epub 2010 Jun 29.

Pharmacokinetics of oral taurine in healthy volunteers

Mohammadreza Ghandforoush-Sattari  1 , Siminozar Mashayekhi, Channarayapatna V Krishna, John P Thompson, Philipp A Routledge
Affiliations

Pharmacokinetics of oral taurine in healthy volunteers

Mohammadreza Ghandforoush-Sattari et al. J Amino Acids. 2010.

Abstract

Taurine, a sulfur-containing amino acid, is a normal constituent of the human diet. Little is known of the pharmacokinetics of taurine in man after oral administration. We studied the pharmacokinetics of 4 g taurine in eight healthy male volunteers (median age 27.5, range 22-45) following orally administration in the fasting state in the morning. Blood samples were taken at regular intervals and plasma taurine concentration was measured by a modified HPLC method. Data were subjected to noncompartmental analysis. Maximum plasma taurine concentration (C(max)) was measured at 1.5 ± 0.6 hr after administration as 86.1 ± 19.0 mg/L (0.69 ± 0.15 mmol). Plasma elimination half-life (T(1/2)) and the ratio of clearance/bioavailability (Cl/F) were 1.0 ± 0.3 hr and 21.1 ± 7.8 L/hr, respectively. Since taurine is occasionally used in therapeutics as a medicine, the pharmacokinetics and effects of oral taurine in healthy volunteers would be useful in the future studies of taurine in pharmacology and nutrition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Linear plot of mean plasma taurine levels (mmoL) in eight healthy volunteers following administration of 4 g (32 mmoL) oral taurine.
Figure 2
Figure 2
Changes in plasma taurine (mmoL) from baseline in eight healthy volunteers following administration of 4 g (32 mmoL) oral taurine.
See this image and copyright information in PMC

References

    1. Huxtable R, Sebring L. Cardiovascular actions of taurine. In: Kuriyama K, Huxtable R, Iwata H, editors. Sulfur Amino Acids Biochemical Aspects. New York, NY, USA: Alan R. Liss; 1983. pp. 5–37.
    1. Jacobsen JG, Smith LH. Biochemistry and physiology of taurine and taurine derivatives. Physiological Reviews. 1968;48(2):424–511. - PubMed
    1. Waterfield CJ, Turton JA, Scales MD, Timbrell JA. Taurine, a possible urinary marker of liver damage: a study of taurine excretion in carbon tetrachloride-treated rats. Archives of Toxicology. 1991;65(7):548–555. - PubMed
    1. Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H. Effect of taurine on the fatty liver of children with simple obesity. Advances in Experimental Medicine and Biology. 1996;403:607–613. - PubMed
    1. Yamauchi-Takihara K, Azuma J, Kishimoto S. Taurine protection against experimental arterial calcinosis in mice. Biochemical and Biophysical Research Communications. 1986;140(2):679–683. - PubMed